|
|
Post by agedhippie on Jan 9, 2024 16:58:01 GMT -5
...Based on past experience BP will throw the kitchen sink at MNKD and getting insurance coverage is not changing... BP stopped caring the day Sanofi dumped Afrezza. Their view was that if Sanofi (ie. a BP like them) cannot make it work then it has no future. The killer was the PBMs and the lack of insurance cover, and that was to do with pricing and bundle negotiations (you can have blockbuster drug X cheap if you give me an exclusive on these other drugs.) MNKD and other small pharmas are collateral damage in the fight between the BP companies - when elephants fight, it is the grass that suffers. |
|
|
|
Post by prcgorman2 on Jan 9, 2024 18:10:41 GMT -5
This is where changing the label, potentially the Standard Of Care, and DTC advertising and marketing may help, but the bottom-line is the bottom-line and somehow the cost of Afrezza has to be competitive to the moms. It saddens me that improved compliance and outcomes don't carry more weight with insurance providers because that's the other angle that should be persuasive.
|
|
|
|
Post by agedhippie on Jan 9, 2024 19:08:13 GMT -5
This is where changing the label, potentially the Standard Of Care, and DTC advertising and marketing may help, but the bottom-line is the bottom-line and somehow the cost of Afrezza has to be competitive to the moms. It saddens me that improved compliance and outcomes don't carry more weight with insurance providers because that's the other angle that should be persuasive. Changing the label would definitely help. Changing the SoC will take proper trial data and there are no plans for that beyond what is in flight. DTC and marketing will fail for the same reason that they did last time - negative endos, poor insurance cover, and general inertia. To change the story do a decent sized trial over six months with a six month extension and show the benefits, not the features. That will move the needle. |
|
|
|
Post by prcgorman2 on Jan 9, 2024 19:50:12 GMT -5
What is a “decent sized trial”?
|
|
|
|
Post by agedhippie on Jan 9, 2024 22:16:15 GMT -5
What is a “decent sized trial”? I would say around 300 people per arm. The truly pivotal trials like DCCT or UKPDS have thousands, but really only governments can run those. If you look at the SURPASS-2 trial Lilly ran which was comparing Mounjaro with Ozempic via a clever bit of framing to avoid the FDA getting upset (you aren't meant to compare with competitors) there were just under 450 people in each of 4 arms. Having large numbers makes the result less arguable as while you might get an outlier group of 5 people in a 100 person arm that's 5% of the arm which doctors will care about, if it's a 450 person arm it's 1% and doctors will be a lot more relaxed. This is why small trials never get traction as that group of 5 would be large percentage of the end result. |
|
|
|
Post by prcgorman2 on Jan 10, 2024 7:16:52 GMT -5
Thank you agedhippie. From your keyboard to MannKind’s Board...
|
|
|
|
Post by sayhey24 on Jan 10, 2024 8:16:33 GMT -5
This is where changing the label, potentially the Standard Of Care, and DTC advertising and marketing may help, but the bottom-line is the bottom-line and somehow the cost of Afrezza has to be competitive to the moms. It saddens me that improved compliance and outcomes don't carry more weight with insurance providers because that's the other angle that should be persuasive. Changing the label would definitely help. Changing the SoC will take proper trial data and there are no plans for that beyond what is in flight. DTC and marketing will fail for the same reason that they did last time - negative endos, poor insurance cover, and general inertia. To change the story do a decent sized trial over six months with a six month extension and show the benefits, not the features. That will move the needle. What trial are you suggesting and for what market T1 or T2? Are you saying the kids trial is not good enough? At this point we have Cipla results coming in for the T2s, the pump/switch and kids for T1. What other trial do you want to show insulin works? At this point the focus needs to be on getting afrezza past the insurance blockade and through the inertia. |
|
|
|
Post by sayhey24 on Jan 10, 2024 8:42:24 GMT -5
...Based on past experience BP will throw the kitchen sink at MNKD and getting insurance coverage is not changing... BP stopped caring the day Sanofi dumped Afrezza. Their view was that if Sanofi (ie. a BP like them) cannot make it work then it has no future. The killer was the PBMs and the lack of insurance cover, and that was to do with pricing and bundle negotiations (you can have blockbuster drug X cheap if you give me an exclusive on these other drugs.) MNKD and other small pharmas are collateral damage in the fight between the BP companies - when elephants fight, it is the grass that suffers. I love it - "when elephants fight, it is the grass that suffers". Mike not only has the nuclear bomb but he now has the nuclear codes. There won't be any grass left. |
|
|
|
Post by hopingandwilling on Jan 10, 2024 9:05:47 GMT -5
|
|
|
|
Post by peppy on Jan 10, 2024 9:15:55 GMT -5
I take it from your words, Mannkind, Afrezza, or Diabetes are not present. ? |
|
|
|
Post by sayhey24 on Jan 10, 2024 9:36:07 GMT -5
|
|
|
|
Post by Thundersnow on Jan 10, 2024 10:37:03 GMT -5
3 complex products undergoing clinical trails, with filings targeted in FY 2024 & FY 2025 • Plan to launch 1 peptide product in FY 2024 and 3-4 peptide products in FY 2025 $ Mn North America Q2 FY24 YoY 11 P ------- I ASSUME the "1 PEPTIDE PRODUCT" is AFREZZA?  ? |
|
|
|
Post by agedhippie on Jan 10, 2024 19:20:58 GMT -5
3 complex products undergoing clinical trails, with filings targeted in FY 2024 & FY 2025 • Plan to launch 1 peptide product in FY 2024 and 3-4 peptide products in FY 2025 $ Mn North America Q2 FY24 YoY 11 P ------- I ASSUME the "1 PEPTIDE PRODUCT" is AFREZZA? ? Not unless they are selling Afrezza in North America (slide title: North America: Robust momentum in differentiated portfolio). |
|
|
|
Post by daisyz on Jan 29, 2024 16:27:32 GMT -5
Afrezza, 2023 - Blue Shield, CA, Silver copay was $250. 2024 it's $538.57. Box of 4s and 8s. Complete BS I'm finally getting around to order more Afrezza and was going through the steps on Mannkind website to contact them on how to get my Afrezza at a lower cost. I went back into the app of my pharmacy to confirm my co-pay and, surprise surprise, the co-pay is now $0. I placed my order and will keep you updated. |
|
|
|
Post by sr71 on Jan 29, 2024 18:25:51 GMT -5
Afrezza, 2023 - Blue Shield, CA, Silver copay was $250. 2024 it's $538.57. Box of 4s and 8s. Complete BS I'm finally getting around to order more Afrezza and was going through the steps on Mannkind website to contact them on how to get my Afrezza at a lower cost. I went back into the app of my pharmacy to confirm my co-pay and, surprise surprise, the co-pay is now $0. I placed my order and will keep you updated. daisyz - That's fantastic news, and please do let us know if that's still the co-pay when you pickup the Rx 
Your post here is the first here that I recall indicating No Co-Pay for Afrezza. If this is in fact the case, the Mannkind sales team will have new ammo to succeed in selling Afrezza!
Also, it should really help VDEX to more easily prescribe and on-board patients with the treatment.
|
|
? 
